Lymphomatoid granulomatosis: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
Revision as of 12:59, 18 March 2025
Lymphomatoid granulomatosis (also known as LYG or LG) is a rare lymphoproliferative disorder characterized by lymphoma-like symptoms. It is associated with Epstein-Barr virus (EBV) infection and is considered a form of angiocentric lymphoma.
Epidemiology
Lymphomatoid granulomatosis is a rare disease, with an estimated incidence of less than 1 in 1,000,000. It affects both sexes equally and can occur at any age, although it is most common in middle-aged adults.
Pathophysiology
The disease is characterized by an abnormal proliferation of B cells that are infected with the Epstein-Barr virus. These cells infiltrate the lungs, skin, kidney, central nervous system and other organs, causing inflammation and damage.
Clinical Presentation
Patients with lymphomatoid granulomatosis typically present with nonspecific symptoms such as fever, weight loss, cough, and shortness of breath. Skin lesions, neurological symptoms, and kidney problems may also occur.
Diagnosis
Diagnosis of lymphomatoid granulomatosis is based on clinical symptoms, imaging studies, and biopsy of affected tissues. The presence of EBV-infected B cells in the biopsy sample is a key diagnostic feature.
Treatment
Treatment options for lymphomatoid granulomatosis include chemotherapy, radiation therapy, and immunotherapy. The choice of treatment depends on the severity of the disease and the patient's overall health.
Prognosis
The prognosis of lymphomatoid granulomatosis is variable, with some patients achieving long-term remission while others experience rapid disease progression.
